| Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations (NCT05807126) | National Cancer Institute (NCI) | 2024-03-05 |
| Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors (NCT06176989) | National Cancer Institute (NCI) | 2024-03-04 |
| Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer (NCT05904080) | National Cancer Institute (NCI) | 2024-02-19 |
| Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer (NCT06161506) | National Cancer Institute (NCI) | 2024-02-15 |
| Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) (NCT05564403) | National Cancer Institute (NCI) | 2024-02-09 |
| Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors (NCT06169124) | National Cancer Institute (NCI) | 2024-02-08 |
| Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma (NCT05711615) | National Cancer Institute (NCI) | 2024-02-06 |
| Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study (NCT05987241) | National Cancer Institute (NCI) | 2024-02-02 |
| PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications (NCT06161519) | National Cancer Institute (NCI) | 2024-01-31 |
| Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma (NCT05960773) | National Cancer Institute (NCI) | 2024-01-31 |
| Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin (NCT05375825) | National Cancer Institute (NCI) | 2024-01-31 |
| Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial (NCT05886036) | National Cancer Institute (NCI) | 2024-01-23 |
| Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial (NCT05773274) | National Cancer Institute (NCI) | 2024-01-12 |
| Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial (NCT05361811) | National Cancer Institute (NCI) | 2024-01-10 |
| Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment (NCT05859334) | National Cancer Institute (NCI) | 2024-01-04 |
| Obeticholic Acid for Prevention in Barrett's Esophagus (NCT04939051) | National Cancer Institute (NCI) | 2024-01-03 |
| Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells (NCT05691465) | National Cancer Institute (NCI) | 2023-12-27 |
| Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency (NCT06090669) | National Cancer Institute (NCI) | 2023-12-19 |
| Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer (NCT05950464) | National Cancer Institute (NCI) | 2023-12-18 |
| Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma (NCT05286827) | National Cancer Institute (NCI) | 2023-12-14 |
| Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial (NCT05554367) | National Cancer Institute (NCI) | 2023-12-13 |
| Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer (NCT05836584) | National Cancer Institute (NCI) | 2023-12-06 |
| Evaluation of Broccoli Seed and Sprout Extract for Detoxification of Carcinogens in Firefighters (NCT06009926) | National Cancer Institute (NCI) | 2023-12-04 |
| Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 Deficiency (NCT05907746) | National Cancer Institute (NCI) | 2023-11-29 |
| Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer (NCT06058377) | National Cancer Institute (NCI) | 2023-11-27 |
| Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer (NCT04808427) | National Cancer Institute (NCI) | 2023-11-20 |
| Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes (NCT05918055) | National Cancer Institute (NCI) | 2023-11-14 |
| Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers (NCT05803382) | National Cancer Institute (NCI) | 2023-11-08 |
| Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer (NCT05996523) | National Cancer Institute (NCI) | 2023-11-07 |
| Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial (NCT05967286) | National Cancer Institute (NCI) | 2023-10-23 |
| Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor (NCT05616650) | National Cancer Institute (NCI) | 2023-10-19 |
| Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer (NCT05828082) | National Cancer Institute (NCI) | 2023-10-16 |
| Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial (NCT05564416) | National Cancer Institute (NCI) | 2023-10-12 |
| Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane (NCT05146739) | National Cancer Institute (NCI) | 2023-10-10 |
| Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness (NCT05691491) | National Cancer Institute (NCI) | 2023-09-28 |
| Omics of Cancer: OncoGenomics (NCT05431439) | National Cancer Institute (NCI) | 2023-09-27 |
| Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial (NCT05715281) | National Cancer Institute (NCI) | 2023-09-26 |
| Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer (NCT05673200) | National Cancer Institute (NCI) | 2023-09-25 |
| Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial (NCT05554380) | National Cancer Institute (NCI) | 2023-09-22 |
| Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers (NCT05691504) | National Cancer Institute (NCI) | 2023-09-14 |
| Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors (NCT05724108) | National Cancer Institute (NCI) | 2023-08-30 |
| Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies (NCT05797233) | National Cancer Institute (NCI) | 2023-08-28 |
| Pilot Prospective Study for PET-CT Imaging in Participants With Relapsed/Refractory Acute Leukemias (NCT05969002) | National Cancer Institute (NCI) | 2023-08-25 |
| A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma (NCT05711628) | National Cancer Institute (NCI) | 2023-08-10 |
| Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors (NCT05372640) | National Cancer Institute (NCI) | 2023-08-10 |
| Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP) (NCT05797246) | National Cancer Institute (NCI) | 2023-08-02 |
| The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN) (NCT04866810) | National Cancer Institute (NCI) | 2023-07-25 |
| Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers (NCT05669664) | National Cancer Institute (NCI) | 2023-07-20 |
| Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial (NCT05554341) | National Cancer Institute (NCI) | 2023-07-14 |
| Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes (NCT05687110) | National Cancer Institute (NCI) | 2023-07-06 |
| Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm (NCT05600894) | National Cancer Institute (NCI) | 2023-06-27 |
| Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas (NCT05389423) | National Cancer Institute (NCI) | 2023-06-27 |
| Phase II Randomized Trial of Bethesda Protocol Compared to Cambridge Method for Detection of Early Stage Gastric Cancer in CDH1 Mutation Carriers (NCT04535414) | National Cancer Institute (NCI) | 2023-06-22 |
| CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer (NCT05685602) | National Cancer Institute (NCI) | 2023-06-12 |
| A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine PDS01ADC in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation Therapy (NCT05361798) | National Cancer Institute (NCI) | 2023-06-12 |
| Vaccine Response With NT-I7 (NCT04054752) | National Cancer Institute (NCI) | 2023-05-30 |
| Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer (NCT05411094) | National Cancer Institute (NCI) | 2023-05-22 |
| Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer (NCT05422794) | National Cancer Institute (NCI) | 2023-05-18 |
| A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations (NCT05588141) | National Cancer Institute (NCI) | 2023-05-16 |
| Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment (NCT05600933) | National Cancer Institute (NCI) | 2023-05-15 |
| A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab (NCT05675410) | National Cancer Institute (NCI) | 2023-05-11 |
| Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome (NCT05419011) | National Cancer Institute (NCI) | 2023-05-08 |
| Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial (NCT05554328) | National Cancer Institute (NCI) | 2023-04-25 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial (NCT05564377) | National Cancer Institute (NCI) | 2023-04-07 |
| Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis (NCT05413304) | National Cancer Institute (NCI) | 2023-04-07 |
| Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies (NCT05371054) | National Cancer Institute (NCI) | 2023-04-05 |
| Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers (NCT05538897) | National Cancer Institute (NCI) | 2023-03-31 |
| Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working (NCT05432791) | National Cancer Institute (NCI) | 2023-03-30 |
| Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial (NCT05411081) | National Cancer Institute (NCI) | 2023-03-24 |
| Defining the Natural History of Squamous Cell Carcinoma in Fanconi Anemia (NCT05687149) | National Cancer Institute (NCI) | 2023-03-23 |
| Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyL (NCT05588128) | National Cancer Institute (NCI) | 2023-03-21 |
| Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment (NCT05432804) | National Cancer Institute (NCI) | 2023-03-20 |
| Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers (NCT05063552) | National Cancer Institute (NCI) | 2023-03-13 |
| Rare Tumors and Cancer Predisposition in Individuals and Families (NCT05350761) | National Cancer Institute (NCI) | 2023-03-10 |
| Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (NCT05531786) | National Cancer Institute (NCI) | 2023-03-06 |
| A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma (NCT05691478) | National Cancer Institute (NCI) | 2023-03-03 |
| Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment (NCT05627245) | National Cancer Institute (NCI) | 2023-03-01 |
| A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome (NCT05027945) | National Cancer Institute (NCI) | 2023-02-23 |
| Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors (NCT04665739) | National Cancer Institute (NCI) | 2023-02-03 |
| Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ... (NCT05470491) | National Cancer Institute (NCI) | 2023-01-26 |
| Testing Obeticholic Acid for Familial Adenomatous Polyposis (NCT05223036) | National Cancer Institute (NCI) | 2023-01-19 |
| 18F-DCFPyL PET/CT in Hepatocellular Carcinoma (NCT05009979) | National Cancer Institute (NCI) | 2023-01-18 |
| Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples From Healthy Volunteers Used for Comparative Analysis of Myeloid Malignancies (NCT05588154) | National Cancer Institute (NCI) | 2023-01-11 |
| Imaging and Biopsy of People With HIV-1 Undergoing Analytic Treatment Interruption (NCT05419024) | National Cancer Institute (NCI) | 2023-01-09 |
| CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies (NCT05442515) | National Cancer Institute (NCI) | 2022-12-28 |
| Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer (NCT05198830) | National Cancer Institute (NCI) | 2022-12-15 |
| A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer (NCT05211323) | National Cancer Institute (NCI) | 2022-12-07 |
| BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study (NCT05136196) | National Cancer Institute (NCI) | 2022-12-06 |
| BMS-986253 in Myelodysplastic Syndromes (NCT05148234) | National Cancer Institute (NCI) | 2022-11-29 |
| Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer (NCT04936230) | National Cancer Institute (NCI) | 2022-11-22 |
| Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer (NCT04692675) | National Cancer Institute (NCI) | 2022-11-18 |
| The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation (NCT05436418) | National Cancer Institute (NCI) | 2022-11-18 |
| Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors (NCT05286801) | National Cancer Institute (NCI) | 2022-11-17 |
| Longitudinal Early Advance Care Planning Discussions and Documentation (LEADD) Program: An Exploratory Study in Adolescents and Young Adults (AYAs) Receiving Hematopoietic Stem Cell Transplant (NCT05605574) | National Cancer Institute (NCI) | 2022-11-16 |
| Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma (NCT05256225) | National Cancer Institute (NCI) | 2022-11-16 |
| Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors (NCT05053971) | National Cancer Institute (NCI) | 2022-11-16 |
| Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial (NCT05327010) | National Cancer Institute (NCI) | 2022-11-14 |
| Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients (NCT05078866) | National Cancer Institute (NCI) | 2022-11-10 |
| Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body (NCT05198843) | National Cancer Institute (NCI) | 2022-11-08 |
| Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma (NCT04639843) | National Cancer Institute (NCI) | 2022-11-03 |